ZNTL

Stock ticker: NASDAQ

PRICE

CHANGE

CAPITALIZATION

Zentalis Pharmaceuticals (ZNTL) Earnings Date & Reports

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC)... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

ZNTL is expected to report earnings to rise 1.19% to -67 cents per share on May 07

Zentalis Pharmaceuticals ZNTL Stock Earnings Reports

Q1'25

Est.

$-0.68

Q4'24

Beat

by $0.16

Q3'24

Beat

by $0.05

Q2'24

Missed

by $0.40

Q1'24

Beat

by $0.91

The last earnings report on March 26 showed earnings per share of -67 cents, beating the estimate of -82 cents. With 908.34K shares outstanding, the current market capitalization sits at 92.64M.

View a ticker or compare two or three

Compare

ZNTL

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For ZNTL
(Try 14 days for Free)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

1359 Broadway

Phone

+1 212 433-3791

Employees

168

Web

https://www.zentalis.com